| Autor: |
Bingham S; SmithKline Beecham Pharmaceuticals, Harlow, Essex, UK., King BF, Rushant B, Smith MI, Gaster L, Sanger GJ |
| Jazyk: |
angličtina |
| Zdroj: |
The Journal of pharmacy and pharmacology [J Pharm Pharmacol] 1995 Mar; Vol. 47 (3), pp. 219-22. |
| DOI: |
10.1111/j.2042-7158.1995.tb05782.x |
| Abstrakt: |
The ability of 5-hydroxytryptamine (5-HT) to evoke contractile activity in the gastric Heidenhain pouch was measured in conscious dogs using a method in which 5-HT4 receptor-antagonist activity can be measured in-vivo. At doses of 5-HT which evoked short-lived measurable responses (5 or 10 micrograms kg-1, i.v.), it was found that this activity was greatly reduced by atropine (100 micrograms kg-1, i.v.), but was unaffected by methysergide, methiothepin, ketanserin (each at 100 micrograms kg-1, i.v.) or granisetron (10 or 100 micrograms kg-1, i.v.). At best SDZ 205-557 2-diethylaminoethyl-[2-methoxy-4-amino-5-chloro] benzoate; 100 micrograms kg-1, i.v.) reduced the action of 5-HT in 4/5 animals and increased it in the other but its effects were variable in magnitude and not consistently maintained. However, the more potent and selective 5-HT4-receptor antagonist SB 204070 (1-butyl-4-piperidinylmethyl 8-amino-7-chloro-1, 4-benzodioxan-5-carboxylate hydrochloride) dose-dependently antagonized the 5-HT-evoked contractions in all dogs tested. This action was reversible, but long-lasting with an effective half-life of 18.0h when administered at 1 microgram kg-1. The estimated ID50 value was 0.55 microgram kg-1. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Plný text